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Abstract
Background
Chronic and high dose opioid use may result in adverse events. We analyzed the risk asso-
ciated with chronic and high dose opioid prescription in a Swiss population.
Methods
Using insurance claims data covering one-sixth of the Swiss population, we analyzed recur-
rent opioid prescriptions (�2 opioid claims with at least 1 strong opioid claim) between 2006
and 2014. We calculated the cumulative dose in milligrams morphine equivalents (MED)
and treatment duration. Excluded were single opioid claims, opioid use that was cancer
treatment related, and opioid use in substitution programs. We assessed the association
between the duration of opioid use, prescribed opioid dose, and benzodiazepine use with
emergency department (ED) visits, urogenital and pulmonary infections, acute care hospi-
talization, and death at the end of the episode.
Results
In 63,642 recurrent opioid prescription episodes (acute 38%, subacute 7%, chronic 25.8%,
very chronic (>360 days) episodes 29%) 18,336 ED visits, 30,209 infections, 19,375 hospi-
talizations, and 9,662 deaths occurred. The maximum daily MED dose was <20 mg in
15.8%, 20−<50 mg in 16.6%, 50−<100 mg in 21.6%, and�100 mg in 46%. Compared to
acute episodes (<90 days), episode duration was an independent predictor of ED visits
(chronic OR 1.09 (95% CI 1.03–1.15), very chronic (>360 days) OR 1.76 (1.67–1.86)) for
adverse effects; infections (chronic OR 1.74 (1.66–1.82), very chronic 4.16 (3.95–4.37)),
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and hospitalization (chronic: OR 1.22 (1.16–1.29), very chronic OR 1.82 (1.73–1.93)). The
risk of death decreased over time (very chronic OR 0.46 (0.43–0.50)). A dose dependent
increased risk was observed for ED visits, hospitalization, and death (�100mg daily MED
OR 1.21 (1.13–1.29), OR 1.29 (1.21–1.38), and OR 1.67, 1.50–1.85, respectively). A con-
comitant use of benzodiazepines increased the odds for ED visits by 46% (OR 1.46, 1.41–
1.52), infections by 44% (OR 1.44, 1.41–1.52), hospitalization by 12% (OR 1.12, 1.07–1.1),
and death by 45% (OR 1.45, 1.37–1.53).
Conclusion
The length of opioid use and higher prescribed morphine equivalent dose were indepen-
dently associated with an increased risk for ED visits and hospitalizations. The risk for infec-
tions, ED visits, hospitalizations, and death also increased with concomitant
benzodiazepine use.
Background
Chronic pain is a leading cause for years lived with disability worldwide [1]. Effective pain
management is needed to decrease pain-associated disability and improve the quality of life.
Since the 1990ies the World Health Organizations’ (WHO) pain relief ladder [2, 3] has been
used to improve pain control in cancer and non-cancer patients. A stepwise increase of treat-
ment intensity in cancer pain is recommended with non-opioids being the first choice for
mild pain. Weak opioids (e.g., tramadol, codeine) are recommended for mild to moderate
pain, and for severe pain, strong opioids (e.g., morphine, fentanyl) [3]. Advocacy for pain con-
trol, advertisement of efficacy of opioids for chronic pain based on low level evidence, and
aggressive prescription practices by physicians resulted in an increased use of opioids for can-
cer and non-cancer related pain [4–6].
Whereas opioids are well established for the relief of acute severe pain in patients with
active cancer, strong opioids are no more effective in chronic non-cancer pain than non-opi-
oid medications [7–9]. Due to the potential adverse events [9–11], opioids are considered sec-
ond line drugs [7–9]. Despite these recommendations, opioids (particularly strong opioids)
are increasingly prescribed for chronic non-cancer pain and the use of strong opioids has
reached enormous dimensions in some countries [12–14]. In parallel to a steep increase in the
opioid use in the US [7], an increase in unintentional opioid overdose and higher hospital
admission rates has been observed [15–19]. In Europe, only limited information on the impact
of chronic opioid use is available. Studies in Europe also showed an increased use of strong
opioids [20–24], but the consequences are less well described in the literature. A study using a
clinical database for primary care practices in the UK reported an increased risk for serious
adverse events such as major trauma, addiction and overdose in chronic opioid use [25]. In
Switzerland, the use of strong opioids more than doubled between 2006 and 2013 [26]. The
implications of chronic opioid use for non-cancer pain remain unknown.
The aim of this study was to assess the risk of adverse events in recurrent opioid use for
non-cancer pain in a representative sample of the Swiss population. We hypothesized that
long-term opioid use and higher opioid doses are associated with a higher rate of adverse
events.
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Methods
Sources of data
In Switzerland, compulsory basic health insurance is universal and covers the population of
8.2 million persons with a comprehensive benefits package defined by federal authorities [27].
The study cohort was identified from the computerized insurance claims database from one of
the major health insurers in Switzerland. The Helsana insurance group covers 1.2 million indi-
viduals (approximately one-sixth of the Swiss population) in all 26 administrative regions (can-
tons). The patient-level linked database provides information on socio-demographic data,
health insurance status, prescribed drugs, health care encounters for pharmacy, hospital, out-
patient, and nursing home services. In case of death, the date of death is also included in the
database. The study population was limited to beneficiaries with full compulsory insurance
coverage during the observation period. All persons ever involved in a drug substitution pro-
gram were excluded.
The Swiss health care system is highly decentralized and no centralized opioid registry is
available. Opioids cannot be purchased over the counter and for strong opioids, a special pre-
scription with a unique identification number (a so called “prescription for narcotic sub-
stances”) is issued with 3 copies. One copy remains with the prescribing physician, one with
the pharmacy, and one with the insurance company. Although the regulation minimizes the
risk of abuse, potential misuse (e.g. multiple prescribers) cannot be identified because no cen-
tral database exists. Further, pharmacies send their bills directly to the insurance company.
Therefore, opioid claims cover close to 100% of all prescribed opioids.
Study cohort
The study cohort included adult patients (aged 18 years and older) with recurrent opioid
claims between January 2006 and December 2014 were included [28]. Recurrent opioid use
was defined as�2 consecutive opioid claims including at least 1 strong opioid claim. We iden-
tified opioid claims using unique codes for the pharmaceutical class based on the WHO phar-
macological Anatomical Therapeutic Chemical (ATC) classification system (S1 Table [29]).
Opioids were defined as weak in opioid formulations with a morphine conversion factor of 0.3
or less (N02AA59 (codeine and combinations), N02AX01 (tilidine), N02AX02 (tramadol),
and N02AX06 (tapentadol)). All opioids with a morphine conversion factor of>0.3 were
defined as strong.
We excluded opioid use related to cancer treatment. Cancer-related use was defined when a
cancer specific treatment occurred (�1 pre-specified ATC or outpatient Swiss tariff positions
(Tarmed) codes, S2 Table) within three months before and after the first filled opioid prescrip-
tion. As insurance companies reimburse opioid use in substitution programs since 1999, we
identified cases using specific reimbursement codes (Tarmed Position 00.0155, positions spe-
cifically assigned to substitution programs in pharmacies or substitution centers for buprenor-
phine, methadone, heroin, and morphine). All people were excluded when a substitution code
was identified (e.g., in a patient, the unique code was identified in the database in 2009 then all
opioids reimbursed for this person were excluded). In addition, we excluded diamorphine
using the corresponding ATC-code (N07BC06 Diaphin1). Other specific brands are used
within substitution programs and for pain treatment: Sevre-Long1 (morphine, N02AA01),
Subutex1 (N07BC01) and Temgesic1 (N02AE01, both buprenorphine), or L-Polamidon1
(N07BC05) and Ketalgin1 (N07BC02, both methadone). These medications were included in
the analysis as long as no code for a substitution program was detected. We excluded patients
with recurrent prescription of Subutex1 sublingual (not excluded by the above-defined
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criteria), when the daily dose was more than 640mg morphine equivalent assuming that Subu-
tex1 was used within an “off-label” opioid substitution.
Medication exposure
An episode of opioid treatment began on the day a patient filled the first opioid prescription.
The duration of an opioid episode was calculated using the difference (in days) between the
date the initial prescription was dispensed and the run-out date of the last prescription dis-
pensed plus 1 [30]. In case of several claims, the time between the last two claims and the calcu-
lated average daily dose (see below) were used to calculate the run-out date. An opioid episode
ended when three months after the calculated run-out date, no new claim was filled. We con-
sidered the follow-up period of 7 days after the first opioid claim until the end of the episode
for all endpoints. Episodes lasting beyond December 2014 were censored by December 31,
2014.
Definitions
We used the following definitions proposed by von Korff et al [30]:
Morphine equivalents per episode. MED for each prescription dispensed during the epi-
sode. Each reimbursement of an opioid medication (referred to hereafter as a “claim”) was
converted to morphine equivalent dose (MED) as follows: Strength of opioid drug in mg per
unit x quantity of units per reimbursed package x number of packages x conversion factor for
morphine equivalents. The equianalgesic dose conversions are estimates and cannot account
for individual variability in genetics and pharmacokinetics. Wherever available we used con-
version factors provided by the Swiss Agency for Therapeutic Products (Swissmedic, agency
comparable to the US Food and Drug Administration, FDA) or the morphine equivalent con-
version factor per mg of opioid was based on the CONSORT classification (CONsortium to
Study Opioid Risks and Trends [30]). Further, we consulted the literature relevant to the topic
and a clinical pharmacologist (See S1 Table: opioids, examples of brand names, the morphine
equivalent conversion factors, and the route of administration).
The MED calculation for patches was based on the assumption that one patch delivers opi-
oids over a time provided by the manufacturer. For example, fentanyl patches deliver the dis-
pensed (and bioavailable) mcg per hour over 72 hours. The calculation of the total bioavailable
MED dose in mg equals (mcg/hour (according to the package reimbursed) × 72 hours’ × num-
ber of patches per package × number of packages reimbursed × 100 [fentanyl conversion fac-
tor]) / 1000. The total MED in mg for one package containing 10 fentanyl patches that each
delivers 12mcg per hour is calculated as follows: 12mcg × 72h × 10
patches × 100 = 864,000mcg/1000 = 864mg. For transdermal buprenorphine patches the
assumption is that one patch delivers the dispensed (and bioavailable) mcg per hour over 96
hours. The total MED dose in milligram equals (mcg/h according to the package reim-
bursed × 96 hours’ × number of patches per package × number of packages reimbursed × 95
[buprenorphine conversion factor]) / 1000.
Duration of episode. Episodes were categorized by their duration into acute (<90 days),
subacute (�90 to<120 days or <10 claims), chronic (�90 days and�10 claims or�120 days’
supply of opioids, and very chronic use (>360 days)) [30].
Average daily dose. Total MED for an episode divided by the episode duration (days). In
case of several claims, the MED per treatment day was calculated between two claims and cate-
gorized into one of the four groups: <20;�20 to<50;�50 to<100, and�100mg MED per
day.
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Costs per day. We divided the sum of all reimbursed claims and treatment costs (outpa-
tient and inpatient costs) by the episode duration in days.
Outcome of interest
As primary outcomes, we examined emergency department visits, the occurrence of urogenital
and pulmonary infections, acute care hospitalization, and death during the episode. According
to the definition of the WHO, adverse events are medical occurrences temporally associated
with the use of a medical product, but not necessarily causally related. Adverse events were
included in the analysis when they occurred two weeks or later after the index date of the opi-
oid prescription. Antibiotic medications typically prescribed for urogenital and pulmonary
infections were identified by ACT codes (J01MA02 ciprofloxacin, J01MA06 norfloxacin,
J01EE01 sulfamethoxazole and trimethoprim, J01XX01 fosfomycin) and pulmonary infections
(J01AA02 doxycycline, J01CR02 amoxicillin and enzyme inhibitor, J01CA04 amoxicillin,
J01FA09 clarithromycin, J01MA14 moxifloxacin). The date of death was available within the
database. No cause of death was available for the current analysis. Because no information on
diagnoses and misuse were available in the insurance claims database, we were not able to
assess these two outcomes.
Confounders
Because the risk of ED visits, infections, hospitalization, and death can influence use of opioids
and the choice of the pharmacologic agents, the analysis controlled for 22 confounders poten-
tially associated with opioid use and the outcomes. Confounders included demographic infor-
mation (age, sex), cultural factors (language region of residence), insurance type (additional
private insurance, managed care models), concomitant benzodiazepine use, and comorbid dis-
eases. Comorbid diseases were based on an adapted version of the Chronic Disease Score
(CDS [31, 32]) and categorized into chronic infections, inflammatory disease, renal disease,
endocrine disease, diabetes, pulmonary diseases, liver failure, organ transplant, neurologic dis-
ease, cardiac disease, hyperlipidemia, glaucoma, acid peptic disease, thyroid disease, and gout
(details of the codes are provided in S3 Table). The CDS has been shown to be associated with
health care utilization [31, 33]. Additionally, we included the pharmacological agent of the
strong opioid (i.e. morphine, oxycodone, buprenorphine, fentanyl, hydromorphone, and
pethidine) as a proxy for the complexity of an episode (e.g. opioid rotation with changes of
substances during an episode or preferred use of a substance depending on the clinical situa-
tion). As we did not have information on the indication for opioid prescription and pain
intensity, changes of pharmacological agents within one episode may indicate more complex
pain problems.
Statistical methods
Descriptive statistics included median and interquartile range for the continuous parameters,
and percentages for the categorical outcomes. We compared groups using Kruskal-Wallis test,
Fisher’s exact test, and Chi-square tests wherever appropriate. We fitted logistic regression
models to the binary outcomes of interest including disease duration (acute, subacute, chronic,
very chronic), maximum prescribed dose (<20 mg (reference), 20 -<50 mg, 50 - <100mg,
�100 mg, prescribed active morphine compounds. The following potential relevant confound-
ers were included in the models: age, sex, additional insurance models (i.e. private insurance
policies, managed care models), place of residency (living in an Italian/French or German
speaking canton), chronic infections, chronic inflammatory disease, diabetes, cardiac disease,
renal disease, end stage renal disease, gout, liver failure, organ transplant, thyroid disease, and
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neurologic disease. Results are reported in odds ratio (OR) including the 95% confidence
interval (95% CI). Overall treatment costs were calculated based on all reimbursed in- and out-
patient costs. We calculated the percent increase or decrease in treatment costs using loglinear
model. Results are reported in % in- or decrease including the 95% CI. Statistical analysis was
performed using the statistical programming language R (https://www.r-project.org/) [34].
The following packages were used: DescTools, mvtnorm, foreign, Rcpp, RDCOMClient, and
tcltk.
Ethics statement
This study is based on administrative de-identified insurance claims data handled in compli-
ance with privacy law and regulations. According to the local ethical committee (Ethical com-
mittee of the Canton Zurich, Switzerland) no IRB approval was required. The study was
conducted following the principles of good clinical practice and in accordance with the Decla-
ration of Helsinki.
Results
Out of 591,633 opioid claims, 76,968 recurrent opioid claims were identified. We excluded
13,326 episodes because they were related to a cancer treatment, leaving 63,642 recurrent opi-
oid prescriptions episodes for non-cancer indications for further analysis. The episode dura-
tion was in 38% acute, 7% subacute, 25.8% chronic, and 29% very chronic (Table 1). The
median age of patients was 72 years (IQR 56; 82), the majority were female (65.5%), and 19.0%
of the patients lived in a French or Italian speaking part of Switzerland. The maximum daily
dose was <20 mg in 15.8%, 20−<50 mg in 16.6%, 50−<100 mg in 21.6%, and�100 mg in
46%. The maximum daily dose of�100 mg was used in 34.6% of the acute, 29.2% of the sub-
acute, 41.4% of the chronic, and in 69% of very chronic episodes (>360 days).
The most prevalent treatments observed were for cardiac diseases (60.8%), psychiatric con-
ditions (42.2%), chronic inflammatory diseases (37.7), pulmonary diseases (14.3%), for
chronic infections (10.5%), and diabetes (12.1%). Compared to the acute opioid episodes, the
proportions increased in very chronic episodes for cardiac diseases (40.3 to 81.2%), psychiatric
diseases (21.4 to 66.9%), inflammatory diseases (21.3 to 81.2%), pulmonary diseases (6.6 to
24.7%), chronic infections (5.3 to 18.5%), and diabetes (7.0 to 17.2%).
Outcomes of interest
Overall, 18,336 ED visits, 30,209 infections, 19,375 hospitalizations, and 9,662 deaths occurred
during the opioid episodes. ED visits occurred in 26.6% in acute episodes (n = 4,880), in 5.2%
in subacute (n = 951), in 23.6% during chronic (n = 4,323), and in 44.6% in very chronic epi-
sodes (n = 8,182, Table 2). Infections occurred in 22.3% during acute (n = 6,737), in 5.5% dur-
ing subacute (n = 1,669), in 26.3% in chronic (n = 7,948), and in 45.9% in very chronic (3,855)
episodes. Hospitalizations were in 25% during acute (n = 4,852), in 6.1% during subacute
(n = 1,176), in 25.5% during chronic (n = 4,938), and in 43.4% during very chronic (n = 8,409)
episodes. The majority of deaths occurred during an acute episode (n = 4,309, 44.6%). Deaths
occurred in 5.8% during subacute (n = 562), in 22.5% during chronic (n = 2,173), and in
27.1% in very chronic (n = 2,618).
Risk for ED visits
ED visits occurred in 11.3% in episodes with a daily dose of<20mg compared to 56.4% in epi-
sodes with a daily dose of�100mg (Table 2). After adjustment for potential confounders, we
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found an increased risk for ED visits with an increased duration of opioid use in chronic epi-
sodes (OR 1.09, 95% CI 1.03–1.15, Table 3, Fig 1), very chronic episodes (OR 1.76, 1.67–1.86),
and in opioid episodes with doses�100mg daily MED (OR 1.21, 1.13–1.29). Concomitant use
of benzodiazepines increased the odds by 46% (OR 1.46, 1.41–1.52).
Risk for infections
Infections requiring antibiotic use occurred in 13.5% in episodes of<20mg compared to
53.2% in episodes with a daily dose of�100mg (Table 2). The duration of opioid episode was
Table 1. Baseline characteristics.
Total Acute Subacute Chronic Very chronic p-value
N (%) / median [IQR] / mean (SD)
Number 63’642 (100) 24’220 (38.1) 4’446 (7.0) 16’427 (25.8) 18’549 (29.1)
Age 72.0 [56; 82] 72.0 [55; 82] 71.0 [55; 81] 72.0 [56; 81] 73.0 [58, 82] <0.000
Female 41’699 (65.5) 14’856 (61.3) 2’818 (63.4) 10’740 (65.4) 13’285 (71.6) <0.000
(Semi)private insurance 13’089 (20.6) 5’098 (21.0) 911 (20.5) 3’316 (20.2) 3’764 (20.3) n.s.
Managed care 13’517 (21.2) 6’030 (24.9) 994 (22.4) 3’459 (21.1) 3’034 (16.4) <0.000
Italian / French part 12’068 (19.0) 4’230 (17.5) 810 (18.2) 3’261 (19.9) 3’767 (20.3) <0.000
Daily dose category <0.000
<20 mg 10’054 (15.8) 4’781 (19.7) 1’159 (26.1) 3’082 (18.8) 1’032 (5.6)
20 - <50 mg 10’552 (16.6) 4’992 (20.6) 904 (20.3) 2’915 (17.7) 1’741 (9.4)
50 - <100mg 13’747 (21.6) 6’061 (25.0) 1’085 (24.4) 3’633 (22.1) 2’968 (16.0)
�100 mg 29’289 (46.0) 8’386 (34.6) 1’298 (29.2) 6’797 (41.4) 12’808 (69.0)
Episode Duration 145 [51; 455] 37 [18; 59] 103 [96; 111] 202 [154; 271] 829 [541; 1406] <0.000
Benzodiazepine 21’548 (33.9) 4’634 (19.1) 1’219 (27.4) 5’898 (35.9) 9’797 (52.8) <0.000
Substances
Morphine 20’934 (32.9) 8’154 (33.7) 1’207 (27.1) 4’927 (30.0) 6’646 (35.8) <0.000
Oxycodone_ 25’054 (39.4) 8’398 (34.7) 1’679 (37.8) 6’688 (40.7) 8’289 (44.7) <0.000
Fentanyl 20’832 (32.7) 6’373 (26.3) 1’261 (28.4) 5’369 (32.7) 7’829 (42.2) <0.000
Pethidine 7’400 (11.6) 3’368 (13.9) 640 (14.4) 1’738 (10.6) 1’654 (8.9) <0.000
Buprenorphine 5’798 (9.1) 1’395 (5.8) 314 (7.1) 1’570 (9.6) 2’519 (13.6) <0.000
Hydromorphone 2’227 (3.5) 498 (2.1) 118 (2.7) 536 (3.3) 1’075 (5.8) <0.000
Comorbidities
Chronic infections 6’690 (10.5) 1’276 (5.3) 342 (7.7) 1’639 (10.0) 3’433 (18.5) <0.000
Chronic inflammatory disease 23’990 (37.7) 5’165 (21.3) 1’373 (30.9) 6’587 (40.1) 10’865 (58.6) <0.000
Renal disease 702 (1.1) 120 (0.5) 45 (1.0) 195 (1.2) 342 (1.8) <0.000
End stage renal disease 520 (0.8) 112 (0.5) 24 (0.5) 155 (0.9) 229 (1.2) <0.000
Diabetes 7’696 (12.1) 1’706 (7.0) 570 (12.8) 2’233 (13.6) 3’187 (17.2) <0.000
Pulmonary disease 9’080 (14.3) 1’592 (6.6) 506 (11.4) 2’394 (14.6) 4’588 (24.7) <0.000
Liver failure 5’913 (9.3) 1’102 (4.5) 297 (6.7) 1’426 (8.7) 3’088 (16.6) <0.000
Organ transplant 650 (1.0) 134 (0.6) 38 (0.9) 170 (1.0) 308 (1.7) <0.000
Neurologic disease 3’775 (5.9) 584 (2.4) 177 (4.0) 921 (5.6) 2’093 (11.3) <0.000
Cardiac disease 38’704 (60.8) 9’759 (40.3) 2’713 (61.0) 11’164 (68.0) 15’068 (81.2) <0.000
Thyroid disease 4’929 (7.7) 900 (3.7) 315 (7.1) 1’464 (8.9) 2’250 (12.1) <0.000
Gout 2’531 (4.0) 395 (1.6) 148 (3.3) 706 (4.3) 1’282 (6.9) <0.000
Psychiatric disease 26’837 (42.2) 5’171 (21.4) 1’594 (35.9) 7’664 (46.7) 12’408 (66.9) <0.000
Treatment costs per day# 56.0 [27.5; 119.9] 100.2 [50.0; 223.4] 52.9 [28.3; 113, 4] 43.1 [23.3; 94.2] 34.7 [20.2; 65.6] <0.000
#treatment costs per day (in Swiss Francs): All reimbursed in and outpatient treatment costs.
https://doi.org/10.1371/journal.pone.0238285.t001
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independently associated with an increased risk for infections requiring antibiotic use (chronic
OR 1.74 (1.66; 1.82), very chronic 4.16 (3.95; 4.37)) with no significant dose dependent effect.
Co-prescribing of benzodiazepines increased the odds by 44% (OR 1.44, 1.41–1.52).
Risk for hospitalization
Hospitalizations occurred in 10.7% in episodes of<20mg compared to 54% in episodes with a
daily dose of�100mg (Table 2). An increasing duration of opioid use was associated with an
increased chance for hospitalization (chronic: OR 1.22 (1.16–1.29), very chronic: OR 1.82
(1.73–1.93)). A dose dependent risk was observed (50–<100mg: OR 1.18 (1.10; 1.26),�100mg
OR 1.29 (1.21; 1.38)). Co-prescribing of benzodiazepine increased the odds by 12% (OR 1.12,
1.07–1.16).
Risk of death
Deaths occurred in episodes of<20mg in 7.7% compared to 61.4% in episodes with a daily
dose of�100mg (Table 2). The majority of patients, died during an acute episode. With
increasing episode duration, the risk of death decreased (chronic: OR 0.61, 0.57–0.66, very
Table 2. Summary of adverse events.
ED visits (N = 18,336) Infections (N = 30,209) Hospitalization (N = 19,375) Deaths (N = 9,662)
N (%)
Acute episodes 4,880 (26.6) 6,737 (22.3) 4,852 (25.0) 4,309 (44.6)
Subacute 951 (5.2) 1,669 (5.5) 1,176 (6.1) 562 (5.8)
Chronic 4,323 (23.6) 7,948 (26.3) 4,938 (25.5) 2,173 (22.5)
Very chronic 8,182 (44.6) 3,855 (45.9) 8,409 (43.4) 2,618 (27.1)
Daily dose <20mg 2’070 (11.3%) 4’089 (13.5%) 2’068 (10.7%) 744 (7.7%)
20 - <50mg 2’419 (13.2%) 4’181 (13.8%) 2’796 (14.4%) 1’105 (11.4%)
50 - <100mg 3’509 (19.1%) 5’862 (19.4%) 4’050 (20.9%) 1’876 (19.4%)
�100mg 10’338 (56.4%) 16’077 (53.2%) 10’461 (54.0%) 5’937 (61.4%)
https://doi.org/10.1371/journal.pone.0238285.t002
Table 3. Risk for adverse events.
ED visits Infections Hospitalization Death
OR (95% CI)§
Duration (acute reference)
Subacute duration 0.97 (0.89; 1.05) 1.26 (1.17; 1.35) 1.19 (1.10; 1.29) 0.73 (0.66; 0.82)
Chronic 1.09 (1.03; 1.15) 1.74 (1.66; 1.82) 1.22 (1.16; 1.29) 0.61 (0.57; 0.66)
very chronic (>360 days) 1.76 (1.67; 1.86) 4.156 (3.95; 4.37) 1.82 (1.73; 1.93) 0.46 (0.43; 0.50)
Daily dose (<20mg reference)
20 - <50mg 1.01 (0.94; 1.08) 0.90 (0.85; 0.96) 1.11 (1.03; 1.19) 1.04 (0.93; 1.16)
50 - <100mg 1.05 (0.98; 1.12) 0.93 (0.87; 0.99) 1.18 (1.10; 1.26) 1.19 (1.07; 1.33)
�100mg 1.21 (1.13; 1.29) 0.99 (0.94; 1.06) 1.29 1.21; 1.38) 1.67 (1.50; 1.85)
Co-prescription
Benzodiazepine 1.46 (1.41; 1.52) 1.18 (1.14; 1.23) 1.12 (1.07; 1.16) 1.45 (1.37; 1.53)
ED, emergency department
§Adjusted for age, sex, chronic infections, chronic inflammatory disease, diabetes, cardiac disease, renal disease, end stage renal disease, gout, liver failure, organ
transplant, thyroid disease, neurologic disease, (semi)private insurance status, living in an Italian/French speaking canton, managed care model, and pharmacological
agents as a proxy for the complexity of the episode.
https://doi.org/10.1371/journal.pone.0238285.t003
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chronic: OR 0.46, 0.43–0.50). The risk of death was independently association with higher
daily doses (50–<100mg: OR 1.19, 1.07–1.22;�100mg: OR 1.67, 1.50–1.85). Co-prescribing of
benzodiazepine increased the risk of death by 45% (OR 1.45, 1.37–1.53).
Comorbidities with increased risk for adverse events
Treatments for chronic inflammatory, pulmonary, and psychiatric diseases were consistently
associated with an increased risk for all outcomes (S4 Table). The associations between other
comorbidities and outcomes were less clear. Treatments for renal and neurologic disease were
associated with an increased risk for infections, hospitalizations, and death but not for ED vis-
its. Treatments for cardiac diseases and gout were associated with an increased risk for ED vis-
its, infections, and hospitalization.
Overall treatment costs per day
We found an independent dose-dependent increase in the overall treatment costs per day. In
episodes with�100mg MED the treatment costs per day were 34.9% higher compared to epi-
sode with a maximum daily dose of<20mg MED (Table 4, Fig 2). Co-prescribing of benzodi-
azepine increased the treatment costs per day by +4.3%.
Discussion
The main findings of this study included an increase independent risk for ED visits, hospitali-
zation, and death in patients with higher morphine equivalent dose (MED). The risk was par-
ticularly high in episodes with a maximum dose of 100mg MED or more and increased when
benzodiazepines were co-prescribed. The chance for ED visits, hospitalization, and antibiotic
use increased the longer an episode lasted and was highest in very chronic opioid users (>360
days).
The findings of this study are in line with several previous studies from the UK and the US.
Similar to our study, prescription of long-acting opioids for chronic non-cancer pain, com-
pared to anticonvulsants or cyclic antidepressants, was associated with a significantly increased
Fig 1. Risk for adverse events during chronic opioid use. Odds ratio (95% CI). Adjusted for age, sex, chronic infections, chronic inflammatory disease, diabetes,
cardiac disease, renal disease, end stage renal disease, gout, liver failure, organ transplant, thyroid disease, neurologic disease, (semi)private insurance status, living in an
Italian/French speaking canton, managed care model, and pharmacological agents as a proxy for the complexity of the episode.
https://doi.org/10.1371/journal.pone.0238285.g001
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risk of all-cause mortality [35]. A large cohort study in the primary care setting in the UK
showed an increased risk for serious adverse events such as major trauma, addiction and over-
dose in chronic opioid [25]. The current study revealed in a large sample of patients with
recurrent opioid prescriptions for non-cancer related pain treatment, a dose- and time depen-
dent risk for adverse events in opioid use beyond 90 days. Other studies used insurance claims
data in the US and found similar associations between opioid prescription and fracture risk
[36], risk of overdose [18], and risk of opioid use disorder [37]. Compared to elderly patients
Fig 2. Increase in average daily treatment costs. % increase (95% CI). Adjusted for age, sex, chronic infections, chronic inflammatory disease, diabetes, cardiac disease,
renal disease, end stage renal disease, gout, liver failure, organ transplant, thyroid disease, neurologic disease, (semi)private insurance status, living in an Italian/French
speaking canton, managed care model, and pharmacological agents as a proxy for the complexity of the episode.
https://doi.org/10.1371/journal.pone.0238285.g002
Table 4. Overall treatment costs per day in recurrent opioid use.
% increase (95% CI)†,§
Episode duration (acute reference)
Subacute -52.3 (-53.7; -50.8)
Chronic -64.4 (-65.1; -63.7)
Very chronic -77.3 (-77.8; -76.7)
Maximum daily dose (<20mg reference)
20 - <50mg 9.4 (6.5; 12.5)
50 - <100mg 13.9 (10.9; 17.0)
>100mg 34.9 (31.4; 38.4)
Co-prescription
Benzodiazepine 4.3 (2.6; 6.1)
†Percent increase or decrease treatment costs per day by one unit increase.
§Adjusted for age, sex, chronic infections, chronic inflammatory disease, diabetes, cardiac disease, renal disease, end
stage renal disease, gout, liver failure, organ transplant, thyroid disease, neurologic disease, (semi)private insurance
status, living in an Italian/French speaking canton, managed care model, and pharmacological agents as a proxy for
the complexity of the episode.
https://doi.org/10.1371/journal.pone.0238285.t004
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without opioid use, opioid prescriptions of�50 mg per day resulted in a two-fold increased
fracture risk [36]. The risk for overdose was 8.9% higher in patients with a daily dose of 100mg
or more MED compared 20mg or less [18]. The risk for unintentional overdose increased with
increasing MED dose per day and longer duration [37]. The risk of unintentional overdose
was more likely in long acting compared to short-acting opioids [38].
Concomitant benzodiazepine use is discouraged by guidelines [39, 40] due to the increased
risk of substance use, greater pain severity, higher rate of mental health conditions, ED visits,
and unintentional overdose [41–43]. Our study confirmed that an additional use of benzodiaz-
epines was independently associated with an increased risk for adverse events. We observed in
patients with chronic inflammatory, pulmonary, and psychiatric diseases an increased risk for
all adverse events. Further, renal and neurologic disease were associated with an increased risk
for infections, hospitalizations, and ED visits. Whether this observation indicate that patients
with those comorbidities are at an increased risk for adverse events, when opioid treatments
are prescribed needs to be further investigated.
Strength and limitations
The main strength of this study is large sample of opioid episode identified from a representa-
tive sample of the Swiss population using insurance claims data. The claims data offers the
opportunity to adjust for variables across a wide spectrum of potential confounders. Several
limitations need to be discussed. First, insurance claims data does not include the clinical diag-
nosis and information on disease severity. We tried to mitigate this by adjusting for potential
confounders using chronic disease measures based on the medications that are reimbursed.
Although we found several comorbidities to be associated with an increased risk for adverse
events, we cannot infer causality. Second, the MED dose during the episodes were calculated
based on the claims dates and may result in an over- or underestimation of the true dose that
was prescribed. Third, we do not know whether patients receiving opioids did also take them.
We restricted the analysis to recurrent claims including at least one prescription of a strong
opioids. We therefore assume that we excluded patients with singular or very short use of
opioids.
Implication for clinical practice
Chronic opioid use in non-cancer pain should be initiated only if other treatment options fail
and short-acting opioids at the lowest dose are recommended [40]. A concomitant prescrip-
tion of benzodiazepines should be avoided.
Implication for research
Further prospective studies need to assess the risk of opioid therapy in patients with specific
comorbidities. Additionally, prospective studies need to assess modifiable factors that increase
the risk for adverse events in patients receiving opioid treatments for non-cancer pain.
Conclusion
The length of opioid use and higher prescribed morphine equivalent dose were independently
associated with an increased risk for ED visits and hospitalizations. The risk for infections, ED
visits, hospitalizations, and death also increased with concomitant benzodiazepine use.
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Supporting information
S1 Table. ATC codes, route of administration and morphine equivalents for opioids. Adm.
R, administration route; O, oral; P, parenteral; R, rectal; SL, sublingual; TD, transdermal; N,
nasal; DDD, defined daily dose is the assumed average maintenance dose per day for a drug
used for its main indication in adults (29); U, unit; morpheq, Morphine Equivalent Conversion
Factor (strength of opioid drug in mg per unit x quantity of units per reimbursed package x
number of packages x conversion factor for morphine equivalents. Transmucosal fentanyl
conversion MED in milligram for transdermal fentanyl patches were calculated: (mcg/hour
(according to the package reimbursed) x 72 hours’ x number of patches per package x number
of packages reimbursed x 100 [fentanyl conversion factor]) / 1000. MED in milligram for
transdermal buprenorphine patches were calculated: (mcg/h according to the package reim-
bursed x 96 hours’ x number of patches per package x number of packages reimbursed x 95
[buprenorphine conversion factor]) / 1000. �All DDD are based on the WHO ATC provided
daily dose except for codeine. In Switzerland, codeine is available in combination with paracet-
amol for pain treatment. No DDD from the WHO were available for codeine-combinations.
Therefore, the average treatment dose of the combinations was used to calculate DDD: e.g.
Co-Dafalgan1 four times daily = 4x20mg codeine.
(DOCX)
S2 Table. Summary of codes that define cancer related opioid use.
(DOCX)
S3 Table. Definitions of comorbidities.
(DOCX)
S4 Table. Full models to predict adverse events.
(DOCX)
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